SUBSCRIBE

Biosimilars and lack of resources

 Posted 22/01/2021

The results of a survey carried out by the World Health Organization (WHO) in 2019‒2020 [1] revealed that, despite the efforts of the organization in helping...

more
EMA recommends approval of adalimumab and insul... Biosimilars/News | Posted 22/01/2021
How organizations worldwide are producing HTA r... Biosimilars/Research | Posted 22/01/2021
Generics applications under review by EMA – Jan... Generics/General | Posted 22/01/2021
Key considerations for payers, employers and pa... Reports | Posted 22/01/2021
Canada approves heparin biosimilars Redesca and... Biosimilars/News | Posted 22/01/2021
FDA increases transparency of biosimilar applic... Guidelines | Posted 22/01/2021
Samsung biosimilars: denosumab clinical trials... Biosimilars/General | Posted 22/01/2021
Biosimilars and availability of reference products Biosimilars/Research | Posted 15/01/2021
Biosimilars applications under review by EMA –... Biosimilars/General | Posted 15/01/2021
EC approval for pegfilgrastim biosimilar Nyvepria Biosimilars/News | Posted 15/01/2021
19646665_l
Influence of local policy measures and practice... Biosimilars/Research | Posted 15/01/2021
US guidance on proprietary names Guidelines | Posted 15/01/2021
Positive phase III results for sintilimab plus... Biosimilars/Research | Posted 15/01/2021
Perspectives of prescribing practices in public... Generics/Research | Posted 15/01/2021
Celltrion: Takeda acquisitions and new plant de... Pharma News | Posted 15/01/2021
Regulatory challenges with biosimilars Biosimilars/Research | Posted 08/01/2021
China approves adalimumab copy biological HLX03 Biosimilars/News | Posted 08/01/2021
More national guidance needed on biosimilars in... Biosimilars/Research | Posted 08/01/2021
EMA and FDA accept application for ranibizumab... Biosimilars/News | Posted 08/01/2021
Key considerations for providers in the US bios... Reports | Posted 08/01/2021
16704526_l
A European pharmaceutical strategy promoting ge... Generics/General | Posted 08/01/2021
Phase I study comparing SB8 with reference beva... Biosimilars/Research | Posted 08/01/2021
Biosimilars in Australia – a-flagging and susta... Biosimilars/General | Posted 08/01/2021
DIA 2021 Global Annual Meeting Conferences | Posted 08/01/2021
ST002293
EMA recommends approval of bevacizumab biosimil... Biosimilars/News | Posted 11/12/2020
Scientific, legal and regulatory challenges fac... Biosimilars/Research | Posted 11/12/2020
US market trends in oncology/nephrology support... Reports | Posted 11/12/2020
New Alvotech partnerships in South Africa and C... Pharma News | Posted 11/12/2020
Safety monitoring for immune-modulating biologi... Biosimilars/Research | Posted 11/12/2020
Familiarity with substitution of prescription g... Generics/Research | Posted 11/12/2020
Biosimilar User Fee Act reauthorization Guidelines | Posted 11/12/2020
Biosimilar advances for Samsung Bioepis Biosimilars/General | Posted 11/12/2020
EMA accepts application for bevacizumab biosimi... Biosimilars/News | Posted 04/12/2020
US biosimilars trends in oncology therapeutics Reports | Posted 04/12/2020
Australia approves etanercept and insulin aspar... Biosimilars/News | Posted 04/12/2020
FDA issues Q & A on biosimilars Guidelines | Posted 04/12/2020
Cost savings after switching to generic tacrolimus Generics/Research | Posted 04/12/2020
Real-world data on biosimilars in inflammatory... Biosimilars/Research | Posted 04/12/2020
Genentech sues Centus over Avastin biosimilar Biosimilars/General | Posted 04/12/2020
Study reveals wide variation in US state drug p... Biosimilars/Research | Posted 04/12/2020
22119008_l
FDA accepts application for ranibizumab biosimilar Biosimilars/News | Posted 27/11/2020
Asia Pacific countries: future demand for biosi... Biosimilars/Research | Posted 27/11/2020
The US biosimilars market in 2020 Reports | Posted 27/11/2020
19646665_l
Biosimilar toolkit for cancer patients Biosimilars/General | Posted 27/11/2020
Biopharmaceuticals and biosimilars: regulatory... Biosimilars/Research | Posted 27/11/2020
Equivalent adherence with brand and generic ost... Generics/Research | Posted 27/11/2020
FDA new and revised guidances for complex gener... Guidelines | Posted 27/11/2020
Pfizer sues Aurobindo and Dr Reddy’s over Ibran... Generics/General | Posted 27/11/2020
Canada approves enoxaparin biosimilars Inclunox... Biosimilars/News | Posted 20/11/2020
more

NON-BIOLOGICAL COMPLEX DRUGS

FDA issues final guidance on liposome drug products Posted 27/04/2018

On 4 April 2018, the US Food and Drug Administration (FDA) issued a new draft...

more


FDA approves 40 mg follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 09/03/2018
Mylan launches first follow-on glatiramer aceta... Non‐Biological Complex Drugs/News | Posted 15/02/2018
Biosimilars and follow-on NBCDs for MS in Europ... Non‐Biological Complex Drugs/Research | Posted 19/01/2018
Impax announces FDA approval of follow-on sevel... Non‐Biological Complex Drugs/News | Posted 17/11/2017
FDA approves follow-on version of sevelamer Non‐Biological Complex Drugs/News | Posted 30/06/2017
Challenges in the regulation of NBCDs Non‐Biological Complex Drugs/Research | Posted 12/05/2017
Scientific and regulatory considerations for fo... Non‐Biological Complex Drugs/Research | Posted 04/05/2017
Equivalence of complex drug products Non‐Biological Complex Drugs/Reports | Posted 14/04/2017
Follow-up studies needed to ensure safety for f... Non‐Biological Complex Drugs/Research | Posted 31/03/2017
Warning letter causes delays for follow-on glat... Non‐Biological Complex Drugs/News | Posted 17/03/2017
Is the EU ready for non-biological complex drug... Non‐Biological Complex Drugs/Research | Posted 03/03/2017
Follow-on versions of glatiramer acetate in Rus... Non‐Biological Complex Drugs/News | Posted 24/02/2017
Non-biological complex drugs and pharmacopoeias Non‐Biological Complex Drugs/Research | Posted 10/02/2017
In vitro analysis of follow-on versions of seve... Non‐Biological Complex Drugs/Research | Posted 18/11/2016
Determining the bioequivalence of follow-on iro... Non‐Biological Complex Drugs/Reports | Posted 04/11/2016
FDA to set up abbreviated pathway for complex p... Non‐Biological Complex Drugs/Polices & Legislation | Posted 21/10/2016
Challenges in the assessment of ophthalmic emul... Non‐Biological Complex Drugs/Reports | Posted 07/10/2016
Cancer lab to evaluate bioequivalence of nanosi... Non‐Biological Complex Drugs/News | Posted 23/09/2016
A conference on ‘Equivalence of Complex Drug Pr... Non‐Biological Complex Drugs/News | Posted 09/09/2016
Collaboration to introduce nanotechnologies in... Non‐Biological Complex Drugs/News | Posted 26/08/2016
Iron carbohydrate follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 12/08/2016
Rigorous approach used to approve a follow-on v... Non‐Biological Complex Drugs/Research | Posted 29/07/2016
US guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 10/06/2016
Non-biological complex drugs and their follow-o... Non‐Biological Complex Drugs/Research | Posted 03/06/2016
Is a new pathway for NBCDs on the way in the US? Non‐Biological Complex Drugs/Polices & Legislation | Posted 27/05/2016
Follow-on glatiramer acetate gains European app... Non‐Biological Complex Drugs/News | Posted 13/05/2016
FDA includes follow-on versions in its new cycl... Non‐Biological Complex Drugs/Guidelines | Posted 29/04/2016
Switching between originator and follow-on iron... Non‐Biological Complex Drugs/Research | Posted 22/04/2016
Follow-on intravenous iron formulations in haem... Non‐Biological Complex Drugs/Research | Posted 01/04/2016
Glatiramoid follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/03/2016
FDA includes follow-on versions in its new lipo... Non‐Biological Complex Drugs/Guidelines | Posted 26/02/2016
EU guidelines for follow-on NBCDs Non‐Biological Complex Drugs/Guidelines | Posted 22/01/2016
GDUFA regulatory priorities for 2016 include co... Non‐Biological Complex Drugs/Polices & Legislation | Posted 11/12/2015
Liposomal follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 11/12/2015
Regulations for follow-on NBCDs Non‐Biological Complex Drugs/Reports | Posted 13/11/2015
Status and regulatory issues surrounding follow... Non‐Biological Complex Drugs/Reports | Posted 05/11/2015
Follow-on glatiramer acetate (M356) claimed as... Non‐Biological Complex Drugs/Research | Posted 05/11/2015
EMA issues reflection paper for follow-on versi... Non‐Biological Complex Drugs/Guidelines | Posted 05/11/2015
FDA approves first follow-on version of glatira... Non‐Biological Complex Drugs/News | Posted 05/11/2015
more

Country Focus

All countries

Sign up today to receive weekly news on the latest developments in generic and biosimilar medicines!

Generics News Research General

more

Biosimilars News Research General

more

More editorial sections